I en klinisk undersøgelse rapporterede cirka 1, 2% af patienter behandlet med ViraferonPeg eller interferon alfa- 2b i kombination med ribavirin livstruende psykiatriske bivirkninger under behandling.
220 In a clinical trial, approximately 1.2% of patients treated with ViraferonPeg or interferon alfa-2b in combination with ribavirin reported life-threatening psychiatric events during treatment.